Insmed’s Growth Potential: Catalysts and Strategic Developments Supporting a Buy Rating

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Insmed (INSM – Research Report). The associated price target remains the same with $90.00.

Andrew Fein has given his Buy rating due to a combination of factors that highlight Insmed’s potential for robust growth in the near term. The company is positioned to benefit from several upcoming catalysts, including the anticipated approval and launch of Brensocatib for bronchiectasis patients, which has a PDUFA date set for August 2025. Additionally, the Phase 2b topline results for Treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension patients are expected soon, with promising patient retention rates indicating a positive response.
Furthermore, the Brensocatib Phase 2b BiRCh study for chronic rhinosinusitis without nasal polyps is anticipated by the end of 2025, aiming to impact key symptom scores. The upcoming Phase 3 ENCORE topline results for Arikayce in all MAC lung disease are also expected to bolster the company’s growth. These developments, alongside the strategic changes in the chronic rhinosinusitis landscape, suggest a strong market opportunity for Insmed, supporting Fein’s Buy rating and the $90 price target.

Fein covers the Healthcare sector, focusing on stocks such as Insmed, Neurocrine, and Wave Life Sciences. According to TipRanks, Fein has an average return of -0.5% and a 39.35% success rate on recommended stocks.

In another report released on May 9, Truist Financial also maintained a Buy rating on the stock with a $108.00 price target.